Global Cisplatin Market Growth (Status and Outlook) 2025-2031

According to this study, the global Cisplatin market size will reach US$ million by 2031.

Cisplatin is one of the most commonly used drugs in current combined chemotherapy. Its chemical name is cis-dichlorodiaminoplatin, which is an inorganic metal complex. After chlorine dissociation, it cross-connects with the DNA of cancer cells, thus damaging the function of DNA.It may form intracyclic Chemicalbook or cross-linking with DNA, or it may form cross-linking with DNA and proteins, and inhibit cell mitosis. It is a non-specific drug in cell cycle, which can inhibit lymphocyte transformation in addition to anticancer, has immunosuppressive effect, and can be used as metal complexes for anticancer drugs.

United States market for Cisplatin is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.

China market for Cisplatin is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.

Europe market for Cisplatin is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.

Global key Cisplatin players cover Eli Lilly and Company, Hospira, Pfizer, Bedford Pharmaceuticals, Alvogen, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2024.

LPI (LP Information)' newest research report, the “Cisplatin Industry Forecast” looks at past sales and reviews total world Cisplatin sales in 2024, providing a comprehensive analysis by region and market sector of projected Cisplatin sales for 2025 through 2031. With Cisplatin sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Cisplatin industry.

This Insight Report provides a comprehensive analysis of the global Cisplatin landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyses the strategies of leading global companies with a focus on Cisplatin portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Cisplatin market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Cisplatin and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Cisplatin.

This report presents a comprehensive overview, market shares, and growth opportunities of Cisplatin market by product type, application, key players and key regions and countries.

Segmentation by Type:
Tablets
Injection

Segmentation by Application:
Testicular Cancer
Osteosarcoma
Breast Cancer

This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Eli Lilly and Company
Hospira
Pfizer
Bedford Pharmaceuticals
Alvogen
Athenex Pharmaceutical
Gland Pharma (Fosun Pharma)
West-Ward Pharmaceuticals
WG Critical Care
David Bull Laboratories
Omega Laboratories
Fresenius Kabi
TEVA
Mylan Pharmaceuticals
Yunnan Plant Pharmaceutical
Yunnan Biological Valley Pharmaceutical
Dezhou de Pharmaceutical
Jiangsu Haosen Pharmaceutical Group
Qilu Pharmaceutical

Please note: The report will take approximately 2 business days to prepare and deliver. Show more